Display options
Cite
Matos E, Zakotnik B, Kuhar CG. Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiol Oncol. 2014;48(4):403-7doi: 10.2478/raon-2013-0081.
Matos, E., Zakotnik, B., & Kuhar, C. G. (2014). Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiology and oncology, 48(4), 403-7. https://doi.org/10.2478/raon-2013-0081
Matos, Erika, et al. "Effectiveness of adjuvant trastuzumab in daily clinical practice." Radiology and oncology vol. 48,4 (2014): 403-7. doi: https://doi.org/10.2478/raon-2013-0081
Matos E, Zakotnik B, Kuhar CG. Effectiveness of adjuvant trastuzumab in daily clinical practice. Radiol Oncol. 2014 Nov 05;48(4):403-7. doi: 10.2478/raon-2013-0081. eCollection 2014 Dec. PMID: 25435855; PMCID: PMC4230562.
Copy Download .nbib Format: NLM
Share it on

Radiol Oncol. 2014 Nov 05;48(4):403-7. doi: 10.2478/raon-2013-0081. eCollection 2014 Dec.

Effectiveness of adjuvant trastuzumab in daily clinical practice.

Radiology and oncology

Erika Matos, Branko Zakotnik, Cvetka Grasic Kuhar

Affiliations

  1. Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia.

PMID: 25435855 PMCID: PMC4230562 DOI: 10.2478/raon-2013-0081

Abstract

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice.

PATIENTS AND METHODS: An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed.

RESULTS: Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021).

CONCLUSIONS: The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.

Keywords: breast cancer; daily clinical practice; trastuzumab, adjuvant

References

  1. Clin Cancer Res. 2013 Sep 15;19(18):4911-6 - PubMed
  2. Radiol Oncol. 2012 Dec;46(4):321-7 - PubMed
  3. N Engl J Med. 2005 Oct 20;353(16):1659-72 - PubMed
  4. N Engl J Med. 2011 Oct 6;365(14):1273-83 - PubMed
  5. Science. 1989 May 12;244(4905):707-12 - PubMed
  6. Science. 1987 Jan 9;235(4785):177-82 - PubMed
  7. N Engl J Med. 2005 Oct 20;353(16):1673-84 - PubMed
  8. Ann Oncol. 2013 Sep;24(9):2206-23 - PubMed
  9. Breast Cancer Res Treat. 2012 Aug;135(1):39-48 - PubMed
  10. Clin Breast Cancer. 2008 Oct;8(5):453-6 - PubMed
  11. J Clin Oncol. 2011 Sep 1;29(25):3366-73 - PubMed
  12. Radiol Oncol. 2013 Mar;47(1):57-62 - PubMed
  13. J Clin Oncol. 2005 Jul 1;23(19):4265-74 - PubMed
  14. Lancet Oncol. 2011 Mar;12(3):236-44 - PubMed
  15. Anticancer Drugs. 2001 Dec;12 Suppl 4:S3-10 - PubMed
  16. Drugs. 2013 May;73(7):755-65 - PubMed
  17. Curr Oncol Rep. 2008 Jan;10(1):10-7 - PubMed
  18. Lancet. 2013 Sep 21;382(9897):1021-8 - PubMed
  19. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  20. N Engl J Med. 2009 Feb 19;360(8):790-800 - PubMed
  21. J Clin Oncol. 2009 Dec 1;27(34):5685-92 - PubMed

Publication Types